查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
印度新興感染疾病診斷市場（按流行病學、應用、技術、感染類型、疾病類型和最終用戶分類）分析與預測（2025-2035 年）
市場調查報告書
商品編碼
1754872

印度新興感染疾病診斷市場（按流行病學、應用、技術、感染類型、疾病類型和最終用戶分類）分析與預測（2025-2035 年）

India Emerging Infectious Disease Diagnostics Market: Focus on Epidemiology, Application, Technology, Type of Infection, Disease Type, and End User - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 100 Pages | 商品交期: 1-5個工作天內

價格

印度新興感染疾病診斷市場規模正在快速成長，這得益於新冠肺炎、瘧疾、結核病和政治熱等感染疾病疫情的不斷增加，以及人們對抗菌素抗藥性日益成長的擔憂。

診斷技術的進步，尤其是分子診斷、就地檢驗和人工智慧，使得快速且準確地檢測病原體成為可能，這對於有效的疾病控制至關重要。國家衛生使命等政府措施和對醫療基礎設施的投資進一步推動了市場的成長。此外，私人公司透過診斷鏈的參與以及與國際公司的合作，也促進了印度各地診斷能力的擴展，特別是在服務不足的地區。由於 COVID-19 大流行而加速的健康意識增強也推動了對及時診斷的需求。因此，市場正在迅速發展，技術創新和可近性的提高進一步促進了新興感染疾病的檢測和治療。

有幾個關鍵因素推動著印度新興感染疾病診斷市場的成長。診斷技術的不斷進步，尤其是 PCR 和 RT-PCR 等分子診斷技術，使得病原體檢測速度更快、更準確。包括 COVID-19、瘧疾、結核病和政治熱在內的感染疾病疫情日益流行，推動了對高效診斷解決方案的需求。此外，國家衛生使命等政府措施以及對醫療基礎設施的投資，提高了診斷工具的可用性和可近性，尤其是在農村地區。由於 COVID-19 疫情的爆發，公眾健康意識增強，重視疾病的早期發現，這進一步推動了市場的成長。此外，私人診斷連鎖店的興起以及與國際診斷公司的合作，正在推動先進診斷技術在印度的普及。這些因素共同推動市場繼續擴張，因為診斷工具的創新和醫療保健可近性的改善將在塑造市場的未來方面發揮關鍵作用。

儘管印度新興的感染疾病診斷市場蘊藏著巨大的機會，但也面臨許多挑戰。其中一項主要挑戰是醫療保健基礎設施的不平衡，尤其是在農村和偏遠地區，這限制了先進診斷技術的普及。雖然城市都市區取得了快速進展，但農村地區診斷設施的匱乏對技術的廣泛應用構成了重大障礙。此外，分子診斷和就地檢驗檢驗等先進診斷測試的高昂成本可能會限制其可負擔性和可近性，尤其對於醫療資源匱乏的人。監管障礙和新診斷技術的核准延遲也減緩了市場成長，因為創新解決方案的引入往往會面臨官僚主義的阻礙。此外，儘管診斷需求不斷成長，但能夠有效操作先進診斷設備的訓練有素的專業人員往往短缺，這阻礙了現有技術的有效利用。這些挑戰凸顯了對醫療保健基礎設施、可負擔性策略和能力建設措施進行重點投資的必要性，以充分發揮印度診斷市場的潛力。

印度新興的感染疾病診斷市場目前正處於快速成長和創新階段。這一階段的特點是，由於感染疾病（尤其是 COVID-19、瘧疾、結核病和政治熱）的流行，先進診斷技術的應用日益廣泛。該市場還受益於政府對醫療基礎設施和診斷能力的大量投資，以及私營部門為擴大診斷工具的取得而做出的參與。分子診斷、就地檢驗和人工智慧的技術進步使得感染疾病檢測更快、更準確，進一步推動了市場成長。在對更有效率、更易獲得的診斷解決方案的需求不斷成長的背景下，由於診斷中心數量的增加以及與國際公司的合作，市場正在不斷擴大。然而，隨著市場的成熟，需要解決定價、基礎設施和監管流程的挑戰。

由於技術進步、公眾健康意識的提升以及政府加強醫療基礎設施的舉措，印度新興感染疾病診斷市場正在快速成長。該行業在應對日益加重的感染疾病負擔、實現及時檢測和改善疾病管理方面發揮關鍵作用。該市場涵蓋廣泛的診斷解決方案，包括分子診斷、就地檢驗和快速診斷檢測 (RDT)，所有這些解決方案都在改變印度的感染疾病控制方式。

印度新興感染疾病診斷領域的主要技術進步包括：

  • 分子診斷：聚合酵素鏈鎖反應(PCR) 和即時PCR(RT-PCR) 等分子診斷技術的採用，徹底改變了我們檢測病原體的能力，使其更加準確、快速。這些技術能夠在基因層面上準確識別病毒和細菌感染，對於快速診斷新冠肺炎 (COVID-19)、結核病和瘧疾等疾病至關重要。
  • 即時檢測 (POCT)：即時檢測設備在印度日益普及，因為它們能夠在患者就診時快速診斷。這在農村和服務欠缺地區尤其重要，因為這些地區缺乏集中式實驗室。快速抗原抗體檢測等即時檢測技術已被證明可有效檢測登革熱、瘧疾和新冠肺炎等疾病。
  • 人工智慧 (AI)：人工智慧和機器學習正日益機會融入診斷平台，使疾病檢測和結果解讀更有效率。人工智慧診斷工具有助於簡化數據分析，從而加快決策速度並改善患者預後。

新興感染疾病診斷對印度的影響：

印度面臨傳染性和非傳染性疾病的雙重負擔，感染疾病持續構成重大公共衛生挑戰。新冠肺炎 (COVID-19)、媒介傳播感染疾病（登革熱、屈公病）以及通用感染疾病等新興感染疾病的興起，迫切需要更先進、更廣泛的診斷工具。

新冠疫情顯著加速了印度診斷檢測的推廣，並凸顯了建立強大的新興感染疾病診斷基礎設施的重要性。這一轉變引起了全球對提升診斷能力需求的關注，並促使公共和私營部門投資加強印度各地的診斷服務。

政府措施和支持

印度政府一直積極主動地透過國家衛生使命（NHM）、國家結核病消除計畫（NTEP）、綜合疾病監測計畫（IDSP）等措施來滿足感染疾病的診斷需求。這些舉措旨在改善疾病監測、早期發現和治療機會，這直接影響了對診斷服務的需求。

為因應新冠肺炎疫情，政府透過擴建實驗室、津貼診斷試劑套件、簡化新診斷技術核准流程等方式加大診斷檢測能力提升力度，顯著提高了印度感染疾病應對能力，並為未來診斷基礎設施發展奠定了基礎。

市場區隔對印度新興感染疾病診斷市場的影響

細分一：按應用

  • 實驗室測試
  • 照護端

實驗室檢驗主導印度新興感染疾病診斷市場（按應用）

從應用角度來看，實驗室檢測領域在2024會計年度佔據了印度新興感染疾病診斷市場的主導地位。實驗室檢測在感染疾病的診斷和管理中發揮著至關重要的作用。它涉及分析患者樣本，例如血液、尿液、痰液和組織，以檢測是否存在傳染源。微生物培養是一種常用技術，將患者樣本在特定的生長培養基中培養，以分離和鑑定細菌、真菌和寄生蟲，然後在顯微鏡下進行觀察。

細分2：依技術

  • 聚合酵素鏈鎖反應（PCR）
  • 恒溫核酸增幅技術（INAAT）
  • 次世代定序儀（NGS）
  • 免疫診斷
  • 其他技術

從技術面來看，2024會計年度，印度新興的感染疾病診斷市場以PCR技術為主。 PCR技術目前已廣泛應用於世界各地的實驗室，因為它可以進一步擴增DNA，甚至能夠分析微量的核酸。隨著分子生物學技術的進步，PCR技術在疾病診斷、DNA分析、精準醫療和基因表現等多個領域得到應用。

次世代定序儀(NGS) 實現了病原體基因組的全面、高通量分析，徹底改變了感染疾病的診斷。全基因組定序 (WGS) 可以對整個病原體基因組進行定序，提供有關遺傳變異、抗菌素抗藥性基因和毒力因子的詳細資訊。 WGS 可用於病原體的識別和表徵、疫情追蹤以及進化模式分析。

預計將實現顯著成長的其他新技術包括數位 PCR、INAAT 和 CRISPR（成簇的規律間隔的短回文重複序列）。

細分3：按感染類型

  • 細菌
  • 病毒性的
  • 真菌
  • 其他感染（例如寄生蟲）

細菌和病毒主導印度新興感染疾病診斷市場（按感染類型）

根據感染疾病類型，細菌感染疾病診斷涉及各種方法和技術，以識別臨床樣本中是否存在細菌病原體。常見的細菌感染疾病包括呼吸道感染疾病，如結核病和鏈球菌感染疾病，以及性行為感染(STI)，如披衣菌感染、淋病和梅毒。

病毒具有變異的能力，因此即使某種病毒已被根除或控制，疾病仍可能捲土重來。正因如此，分子診斷公司正致力於開發能夠檢測多種病毒的檢測方法。常見的感染疾病包括流感病毒、生殖器皰疹病毒、新冠肺炎病毒、肝炎病毒、腮腺炎病毒、德國麻疹、胃腸炎病毒、茲卡和伊波拉出血熱。

細分4：按疾病類型

  • 呼吸道感染疾病
  • 胃腸道感染疾病
  • 性行為感染感染（STI）
  • 神經系統感染疾病
  • 移植後感染疾病
  • 其他

呼吸道感染疾病在印度新興感染疾病診斷市場中占主導地位（按疾病類型）

大多數分子診斷公司提供多種引起呼吸道感染疾病的細菌和病毒的檢測。此外，COVID-19 疫情促使人們開發了一系列使用逆轉錄聚合酶鍊式反應 (RT-PCR) 等傳統技術以及 RT-LAMP 和 CRISPR 等新技術的檢測方法。目前，一些公司提供針對甲型流感、乙型流感、呼吸道融合細胞病毒(RSV) 和 SARS-CoV-2 病毒的多重檢測。

細分 5：按最終用戶

  • 醫院和診所
  • 診斷實驗室
  • 其他

印度新興感染疾病診斷市場以醫院/診所和診斷實驗室為主（按最終用戶）

根據最終用戶，醫院和診所以及診斷實驗室部門在 2024 財政年度佔印度新興感染疾病診斷市場的最大佔有率。醫院和診所在感染疾病診斷領域發揮關鍵作用，是病患評估和檢測的重要中心。除了提供即時結果以快速診斷和管理的就地檢驗(POCT) 之外，醫院和診所還依靠實驗室檢測進行全面分析。一些醫療機構建立了配備最先進診斷技術的內部實驗室，而其他醫療機構則與外部診斷實驗室合作進行專門檢測。這些實驗室採用各種方法，包括 PCR 和定序等分子技術、血清學檢測和基於培養的方法來準確識別和表徵傳染源。

印度：開發新興市場感染疾病診斷市場的最新趨勢

  • 2023年2月，賽默飛世爾科技公司與Mylab宣佈建立傳染病檢查套件合作關係。
  • 2023 年 2 月，生技新興企業CrisprBits 在種子前資金籌措中籌集了 25 萬美元，以支持基於 CRISPR 的測試開發和商業化。
  • 2023年2月，美國食品藥物管理局（FDA）批准Cepheid公司（母公司：DANAHER CORPORATION）的Xpert Mpox檢測緊急使用。
  • 2022 年 8 月，Bio-Rad Laboratories, Inc. 收購了 Curiosity Diagnostics，獲得了 PCR ONE 的使用權，這是 Curiosity Diagnostics 正在開發的一種用於快速檢測多種病原體的技術。
  • 2021年6月，Hologic公司完成對Mobidiag的收購，擴大了分子診斷能力。
  • 2023 年 1 月，CrisprBits 開發了印度首個基於 CRISPR 的 SARS-CoV Year-2 測試。
  • 2023年3月，印度新興企業Mylab Discovery Solutions Pvt. Ltd.與美國第一家分子診斷藥物製造商AstraGene LLC成立合資企業，在美國和科威特開發分子診斷藥物。
  • 2022 年 11 月，Bio-Rad Laboratories, Inc. 與 NuProbe 簽訂了數位 PCR 應用的獨家授權合約。

印度新興感染疾病診斷市場報告如何為您的組織增加價值？

工作流程/創新策略：印度新興感染疾病診斷市場已根據應用、技術、感染疾病類型、疾病類型、最終用戶和地區等不同類別進行了廣泛細分，這有助於讀者清楚地了解哪個細分市場佔有最大佔有率以及哪個細分市場在未來幾年可能成長。

成長/行銷策略產品發布、升級和核准是印度新興感染疾病診斷市場的主要發展。

競爭策略：印度新興感染疾病診斷市場是一個分散的市場，既有參與企業，也有新興的參與企業。本研究分析並概述了印度新興感染疾病診斷市場中的主要企業概況，包括提供各種感染疾病分子診斷測試的現有公司。

本報告研究了印度新興的感染疾病診斷市場，並概述了市場以及流行病學、應用、技術、感染類型、疾病類型、最終用戶和參與市場的公司概況等方面的趨勢。

目錄

執行摘要

第1章 印度新興感染疾病診斷市場概述

  • 市場展望
  • 市場動態

2. 印度新興感染疾病診斷市場分析（按應用），百萬美元，2023-2035

  • 概述
  • 實驗室測試
  • 就地檢驗

3. 印度新興感染疾病診斷市場分析（按技術），百萬美元，2023-2035 年

  • 概述
  • PCR
    • 即時PCR
    • 數位PCR
  • 免疫診斷
  • 恒溫核酸增幅技術（INAAT）
  • 次世代定序（NGS）
  • 其他

4. 印度新興感染疾病診斷市場分析（依感染類型），百萬美元，2023-2035 年

  • 概述
  • 細菌
  • 病毒
  • 真菌
  • 其他

5. 印度新興感染疾病診斷市場分析（按疾病類型），百萬美元，2023-2035 年

  • 概述
  • 呼吸道感染疾病
  • 胃腸道感染疾病
  • 性行為感染感染（STI）
  • 感染疾病
  • 移植後感染疾病
  • 其他

6. 印度新興感染疾病診斷市場分析（按最終用戶分類），百萬美元，2023-2035 年

  • 概述
  • 醫院和診所
  • 診斷實驗室
  • 其他

7. 印度新興感染疾病診斷市場競爭基準化分析與公司概況

  • 競爭基準化分析
  • 競爭格局
    • 各公司主要策略及發展
    • 關鍵進展
    • 企業市場占有率分析
  • 公司簡介
    • Abbott Laboratories
    • Becton, Dickson and Company
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc
    • Co-Diagnostics, Inc.
    • Danaher Corporation
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd
    • Hologic, Inc
    • QIAGEN NV
    • Thermo Fisher Scientific, Inc.
    • Siemens Healthineers AG
  • 新興企業概況
    • Trivitron Healthcare
    • Genes2Me
    • CrisprBits
    • D-NOME Pvt Ltd.

第8章調查方法

Product Code: BHP1447SB

India Emerging Infectious Disease Diagnostics Market Industry Overview

India emerging infectious disease diagnostics market is experiencing rapid growth, driven by the increasing prevalence of infectious diseases, such as COVID-19, malaria, tuberculosis, and dengue, alongside rising concerns about antimicrobial resistance. Technological advancements in diagnostics, particularly in molecular diagnostics, point-of-care testing, and artificial intelligence, are enabling faster and more accurate detection of pathogens, which is crucial for effective disease management. The government's initiatives, such as the National Health Mission and investments in healthcare infrastructure, further bolster the growth of the market. Additionally, the private sector's involvement through diagnostic chains and partnerships with international companies is contributing to the expansion of diagnostic capabilities across India, particularly in underserved regions. The heightened awareness about health, accelerated by the COVID-19 pandemic, has also increased the demand for timely diagnostics. As a result, the market is evolving rapidly, with innovations and improved accessibility driving further advancements in the detection and treatment of emerging infectious diseases.

Several key factors are driving the growth of India's emerging infectious disease diagnostics market. Ongoing advancements in diagnostic technologies, particularly in molecular diagnostics such as PCR and RT-PCR, are enabling faster and more accurate detection of pathogens. The increasing prevalence of infectious diseases, including COVID-19, malaria, tuberculosis, and dengue, has heightened the demand for efficient diagnostic solutions. Furthermore, government initiatives such as the National Health Mission and investments in healthcare infrastructure are enhancing the availability and accessibility of diagnostic tools, particularly in rural areas. The growing awareness of public health and the emphasis on early disease detection, accelerated by the COVID-19 pandemic, have further contributed to market growth. Additionally, the rise of private diagnostic chains and partnerships with international diagnostic companies are increasing the reach of advanced diagnostic technologies across India. These factors collectively position the market for continued expansion, with innovations in diagnostic tools and greater healthcare accessibility playing a pivotal role in shaping its future.

Despite the significant opportunities, several challenges persist in India emerging infectious disease diagnostics market. One of the primary challenges is the uneven healthcare infrastructure, particularly in rural and remote areas, which limits access to advanced diagnostic technologies. While urban centers have seen rapid advancements, the lack of diagnostic facilities in rural regions poses a significant barrier to widespread adoption. Additionally, high costs associated with advanced diagnostic tests, such as molecular diagnostics and point-of-care testing, can limit their affordability and accessibility, especially for underserved populations. Regulatory hurdles and delays in approvals for new diagnostic technologies also slow down the market's growth, as the introduction of innovative solutions often faces bureaucratic obstacles. Furthermore, while the demand for diagnostics is rising, there is often a lack of trained professionals to effectively operate advanced diagnostic equipment, which hampers the effective utilization of available technologies. These challenges highlight the need for targeted investment in healthcare infrastructure, affordability strategies, and capacity-building initiatives to unlock the full potential of the diagnostic market in India.

Market Lifecycle Stage of India Emerging Infectious Disease Diagnostics:

The India Emerging Infectious Disease Diagnostics market is currently in a phase of rapid growth and innovation. This phase is characterized by the increasing adoption of advanced diagnostic technologies, driven by the rising incidence of infectious diseases, particularly COVID-19, malaria, tuberculosis, and dengue. The market is also benefiting from significant government investments in healthcare infrastructure and diagnostic capabilities, as well as from private sector participation in expanding access to diagnostic tools. Technological advancements in molecular diagnostics, point-of-care testing, and artificial intelligence are enabling faster, more accurate detection of infectious diseases, further propelling market growth. As the demand for more efficient and accessible diagnostic solutions grows, the market is in the process of scaling up, with an increasing number of diagnostic centers and partnerships with international companies. However, challenges related to affordability, infrastructure gaps, and regulatory processes still need to be addressed as the market continues to mature.

Impact on India Emerging Infectious Disease Diagnostics

India Emerging Infectious Disease Diagnostics market is experiencing rapid growth, driven by increasing technological advancements, heightened public health awareness, and government initiatives aimed at strengthening healthcare infrastructure. This sector plays a critical role in addressing the growing burden of infectious diseases, enabling timely detection, and improving disease management. The market includes a broad range of diagnostic solutions, such as molecular diagnostics, point-of-care testing, and rapid diagnostic tests (RDTs), all of which are transforming the approach to combating infectious diseases in India.

Key technological advancements in India emerging infectious disease diagnostics include:

  • Molecular Diagnostics: The adoption of molecular diagnostic technologies, such as Polymerase Chain Reaction (PCR) and Real-Time PCR (RT-PCR), has revolutionized the ability to detect pathogens with higher accuracy and speed. These technologies, which allow for the precise identification of viral and bacterial infections at a genetic level, have become indispensable in the rapid diagnosis of diseases such as COVID-19, tuberculosis, and malaria.
  • Point-of-Care Testing (POCT): Point-of-care testing devices have been gaining traction in India, enabling rapid diagnosis at the site of patient care. This is especially important in rural and underserved areas where access to centralized laboratories may be limited. POCT technologies, such as rapid antigen and antibody tests, have proven to be effective in detecting diseases such as dengue, malaria, and COVID-19.
  • Artificial Intelligence (AI): AI and machine learning are increasingly being incorporated into diagnostic platforms, improving the efficiency of disease detection and interpretation of results. AI-driven diagnostic tools are helping streamline data analysis, enabling faster decision-making and better patient outcomes.

Impact of India Emerging Infectious Disease Diagnostics:

India faces a dual burden of communicable diseases and non-communicable diseases, with infectious diseases continuing to pose significant public health challenges. The rise of emerging infectious diseases, such as COVID-19, as well as vector-borne diseases (dengue, chikungunya), and zoonotic diseases, has created an urgent demand for more sophisticated and widespread diagnostic tools.

The COVID-19 pandemic significantly accelerated the adoption of diagnostic testing in India, highlighting the importance of having a robust diagnostic infrastructure for emerging diseases. This shift has brought global attention to the need for improved diagnostic capabilities, and it has encouraged investments in both public and private sectors to enhance diagnostic services across the country.

Government Initiatives and Support:

The Indian government has been proactive in addressing the diagnostic needs for infectious diseases through initiatives such as the National Health Mission (NHM), National Tuberculosis Elimination Program (NTEP), and Integrated Disease Surveillance Program (IDSP). These initiatives aim to improve disease surveillance, early detection, and treatment access, which directly influences the demand for diagnostic services.

In response to COVID-19, the government ramped up efforts to increase diagnostic testing capacity, including expanding testing sites, subsidizing diagnostic kits, and streamlining approval processes for new diagnostic technologies. These actions have significantly improved India's capacity to respond to infectious disease outbreaks and have laid the foundation for future diagnostic infrastructure development.

Market Segmentation for Impact on India Emerging Infectious Disease Diagnostics Market:

Segmentation 1: by Application

  • Laboratory Testing
  • Point of Care

Laboratory Testing to Dominate the India Emerging Infectious Disease Diagnostics Market (by Application)

Based on application, the laboratory testing segment dominated India emerging infectious disease diagnostics market in FY2024. Laboratory testing plays a crucial role in the diagnosis and management of infectious diseases. It involves the analysis of patient samples, such as blood, urine, sputum, or tissue, to detect the presence of infectious agents. Microbiological culture is a common technique that involves incubating patient samples on specific growth media to isolate and identify bacteria, fungi, or parasites, which can then be visualized through microscopy.

Segmentation 2: by Technology

  • Polymerase Chain Reaction (PCR)
  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Next-Generation Sequencing (NGS)
  • Immunodiagnostics
  • Other Technologies

Based on technology, India emerging infectious disease diagnostics market was dominated by the PCR segment in FY2024. Nowadays, PCR is usually used in several laboratories around the world, as it amplifies DNA further, allowing the analysis of even small amounts of nucleic acid. With growing technological advancements in molecular biology techniques, PCR has been utilized in several fields, including disease diagnosis, DNA profiling, precision medicine, and gene expression.

Next-generation sequencing (NGS) has revolutionized infectious disease diagnosis by enabling comprehensive and high-throughput analysis of pathogen genomes. Whole genome sequencing (WGS) allows the sequencing of entire pathogen genomes, providing detailed information about genetic variations, antimicrobial resistance genes, and virulence factors. It can identify and characterize pathogens, track outbreaks, and analyze their evolutionary patterns.

Other emerging technologies anticipated to register significant growth include technologies such as digital PCR, INAAT, and clustered regularly interspaced short palindromic repeats (CRISPR).

Segmentation 3: by Type of Infection

  • Bacterial
  • Viral
  • Fungal
  • Other Infections (Parasitic etc)

Bacterial and Viral Segments to Dominate the India Emerging Infectious Disease Diagnostics Market (by Type of Infection)

Based on the type of infection, bacterial infectious disease diagnosis involves various methods and techniques to identify the presence of bacterial pathogens in clinical samples. Some of the common bacterial infections include respiratory infections such as tuberculosis and streptococcal infections and sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and syphilis.

Viruses have the ability to mutate and, therefore, can lead to the re-emergence of diseases even after one form of the virus has been eradicated or managed. Molecular diagnostic companies are therefore focused on developing tests that can detect a wide range of viruses. Some of the common infections caused by viruses include influenza, genital herpes, COVID-19, hepatitis, mumps, rubella, gastroenteritis, Zika disease, and ebola disease, among others.

Segmentation 4: by Disease Type

  • Respiratory Infections
  • Gastrointestinal Infections
  • Sexually Transmitted Infections (STIs)
  • Neurological Infections
  • Post-Transplant Infections
  • Other Infections

Respiratory Infections to Dominate the India Emerging Infectious Disease Diagnostics Market (by Disease Type)

A vast majority of molecular diagnostic companies offer tests for various kinds of bacteria and viruses responsible for causing respiratory infections. Moreover, the COVID-19 pandemic led to the development of a wide range of tests employing conventional technologies such as reverse transcriptase PCR (RT-PCR) and even leveraging emerging technologies such as RT-LAMP and CRISPR. Several companies now offer multiplex assays that test for influenza A, influenza B, respiratory syncytial virus (RSV), and SARS-CoV-2 virus.

Segmentation 5: by End User

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Other End Users

Hospitals and Clinics and Diagnostic Laboratories to Dominate the India Emerging Infectious Disease Diagnostics Market (by End User)

Based on end users, the hospitals and clinics, and diagnostic laboratories segments accounted for the largest share of the India emerging infectious disease diagnostics market in FY2024. Hospitals and clinics play a critical role in the field of infectious disease diagnostics, serving as important centers for patient evaluation and testing. In addition to point-of-care testing (POCT), which provides immediate results for rapid diagnosis and management, hospitals and clinics may also rely on laboratory testing for comprehensive analysis. Some healthcare facilities have on-site laboratories equipped with state-of-the-art diagnostic technologies, while others collaborate with external diagnostic laboratories for specialized testing. These laboratory facilities employ various methods, including molecular techniques such as PCR and sequencing, serological assays, and culture-based methods to identify and characterize infectious agents accurately.

Recent Developments in the India Emerging Infectious Disease Diagnostics Market

  • In February 2023, Thermo Fisher Scientific Inc. and Mylab announced a pact on test kits for infectious diseases.
  • In February 2023, Biotech startup CrisprBits raised $250,000 in a pre-seed funding round to support the development and commercialization of its CRISPR-based tests.
  • In February 2023, the Food and Drug Administration (FDA) authorized the Xpert Mpox test by Cepheid (parent: DANAHER CORPORATION) for emergency use.
  • In August 2022, Bio-Rad Laboratories, Inc. acquired Curiosity Diagnostics to gain access to PCR ONE, a technology being developed by Curiosity Diagnostics, which can quickly detect a broad range of pathogens.
  • In June 2021, Hologic, Inc. completed the acquisition of Mobidiag to expand its capabilities in molecular diagnostics.
  • In January 2023, CrisprBits developed India's first CRISPR-based SARS-CoV-2 test with Omicron detection.
  • In March 2023, an India-based startup, Mylab Discovery Solutions Pvt. Ltd., entered into a joint venture with AstraGene LLC, the U.A.E.'s first molecular diagnostics manufacturing company to develop molecular diagnostics in the U.A.E. and Kuwait.
  • In November 2022, Bio-Rad Laboratories, Inc. and NuProbe entered into an exclusive licensing agreement for digital PCR applications.

How can India emerging infectious disease diagnostics market report add value to an organization?

Workflow/Innovation Strategy: India emerging infectious disease diagnostics market has been extensively segmented on the basis of various categories, such as application, technology, type of infection, disease type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: In the India emerging infectious disease diagnostics market product launches, upgradations, and approvals accounted for the maximum number of key developments.

Competitive Strategy: The India emerging infectious disease diagnostics market is fragmented with several established as well as emerging players. Key players in the India emerging infectious disease diagnostics market analyzed and profiled in the study involve established players that offer various kinds of molecular diagnostic tests for infectious diseases.

Methodology

Key Considerations and Assumptions in India Emerging Infectious Disease Diagnostics Market Engineering and Validation

  • The base year considered for the calculation of India emerging infectious disease diagnostics market size is 2024. The historical year analysis has been done from FY2021 to FY2023, and the market size has been estimated for FY2024 and projected for the period 2025-2035.
  • The regional distribution of the India emerging infectious disease diagnostics market revenue has been estimated to be the same as the company's net revenue distribution. All the numbers have been adjusted off to two digits after decimal for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. The CAGR has been calculated for the forecast period 2025-2035.
  • The market has been mapped based on different types of products available in the India emerging infectious disease diagnostics market for various applications. All key companies having a significant number of offerings for the India emerging infectious disease diagnostics market have been considered and profiled in the report.
  • The primary respondent's verification has been considered to finalize the estimated market for the India emerging infectious disease diagnostics market.
  • The latest annual reports of each market player have been taken into consideration for India emerging infectious disease diagnostics market revenue calculation.
  • Market strategies and developments of key players have been considered for the calculation of the sub-segment split.
  • The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website.

Primary Research

The key data points taken from the primary sources include:

  • Validation and triangulation of all the numbers and graphs
  • Validation of the report's segmentation and key qualitative findings
  • Understanding of the numbers of the various markets for market type
  • Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

  • National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), World Health Organization (WHO), and Indian Council of Medical Research (ICMR)
  • Annual reports, SEC filings, and investor presentations of the leading market players
  • Company websites and detailed study of their portfolio
  • Gold standard magazines, journals, whitepapers, press releases, and news articles
  • Databases

The key data points taken from the secondary sources include:

  • Segmentations, split-ups, and percentage shares
  • Data for market value
  • Key industry trends of the top players in the market
  • Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
  • Quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis for India Emerging Infectious Disease Diagnostics:

Infectious disease diagnostics encompass a range of methods and techniques used to identify and detect infectious agents in individuals suspected of having an infection. These diagnostics play a vital role in timely diagnosis and accuracy, enabling appropriate treatment decisions and public health interventions.

There are two major approaches in the field; one is microbiological culture, which is a fundamental approach in which patient specimens are cultured on specialized growth media to isolate and identify specific pathogens. This technique allows for the determination of the causative organism and the assessment of its antimicrobial susceptibility. Molecular diagnostics, another important approach, utilizes techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) to detect the genetic material of the infectious agent. This enables highly sensitive and specific identification of pathogens, even at low concentrations.

Some of the prominent companies in India emerging infectious disease diagnostics market are:

  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthcare AG
  • Thermo Fisher Scientific Inc.
  • DANAHER CORPORATION
  • Hologic, Inc.
  • Trivitron Healthcare
  • Genes2Me
  • CrisprBits
  • D-NOME Pvt Ltd
  • Co-Diagnostics, Inc.
  • DiaSorin S.p.A.
  • QIAGEN N.V.

Table of Contents

Executive Summary

Scope of Study

Research Methodology

1. India Emerging Infectious Disease Diagnostics Market Overview

  • 1.1 Market Outlook
    • 1.1.1 Market Overview
      • 1.1.1.1 Epidemiology of Infectious Diseases In India
        • 1.1.1.1.1 Respiratory Infection
          • 1.1.1.1.1.1 Influenza A and B
          • 1.1.1.1.1.1.1 Incidence
          • 1.1.1.1.1.1.2 Diagnosis rate
          • 1.1.1.1.1.1.3 Target Patient Pool
          • 1.1.1.1.1.2 RSV
          • 1.1.1.1.1.2.1 Incidence
          • 1.1.1.1.1.2.2 Diagnosis rate
          • 1.1.1.1.1.2.3 Target Patient Pool
          • 1.1.1.1.1.3 Mycoplasma Infections
          • 1.1.1.1.1.3.1 Incidence
          • 1.1.1.1.1.3.2 Diagnosis rate
          • 1.1.1.1.1.3.3 Target Patient Pool
          • 1.1.1.1.1.4 Pertussis
          • 1.1.1.1.1.4.1 Incidence
          • 1.1.1.1.1.4.2 Diagnosis rate
          • 1.1.1.1.1.4.3 Target Patient Pool
          • 1.1.1.1.1.5 Sexually Transmitted Infections (STIs)
          • 1.1.1.1.1.5.1 Incidence
          • 1.1.1.1.1.5.2 Diagnosis rate
          • 1.1.1.1.1.5.3 Target Patient Pool
          • 1.1.1.1.1.6 HIV/AIDS
          • 1.1.1.1.1.6.1 Incidence
          • 1.1.1.1.1.6.2 Diagnosis rate
          • 1.1.1.1.1.6.3 Target Patient Pool
          • 1.1.1.1.1.7 HPV Infection
          • 1.1.1.1.1.7.1 Incidence
          • 1.1.1.1.1.7.2 Diagnosis rate
          • 1.1.1.1.1.7.3 Target Patient Pool
          • 1.1.1.1.1.8 Herpes
          • 1.1.1.1.1.8.1 Incidence
          • 1.1.1.1.1.8.2 Diagnosis rate
          • 1.1.1.1.1.8.3 Target Patient Pool
          • 1.1.1.1.1.9 Gonorrhoea
          • 1.1.1.1.1.9.1 Incidence
          • 1.1.1.1.1.9.2 Diagnosis rate
          • 1.1.1.1.1.9.3 Target Patient Pool
          • 1.1.1.1.1.10 Syphilis
          • 1.1.1.1.1.10.1 Incidence
          • 1.1.1.1.1.10.2 Diagnosis rate
          • 1.1.1.1.1.10.3 Target Patient Pool
        • 1.1.1.1.2 Gastrointestinal Infections
          • 1.1.1.1.2.1 Colitis
          • 1.1.1.1.2.1.1 Incidence
          • 1.1.1.1.2.1.2 Diagnosis rate
          • 1.1.1.1.2.1.3 Target Patient Pool
          • 1.1.1.1.2.2 Peptic Ulcer
          • 1.1.1.1.2.2.1 Incidence
          • 1.1.1.1.2.2.2 Diagnosis rate
          • 1.1.1.1.2.2.3 Target Patient Pool
          • 1.1.1.1.2.3 Diarrhoea
          • 1.1.1.1.2.3.1 Incidence
          • 1.1.1.1.2.3.2 Diagnosis rate
          • 1.1.1.1.2.3.3 Target Patient Pool
        • 1.1.1.1.3 Neurological Infections
          • 1.1.1.1.3.1 Meningitis
          • 1.1.1.1.3.1.1 Incidence
          • 1.1.1.1.3.1.2 Diagnosis rate
          • 1.1.1.1.3.1.3 Target Patient Pool
          • 1.1.1.1.3.2 Encephalitis
          • 1.1.1.1.3.2.1 Incidence
          • 1.1.1.1.3.2.2 Diagnosis rate
          • 1.1.1.1.3.2.3 Target Patient Pool
        • 1.1.1.1.4 Post-Transplant Infections
          • 1.1.1.1.4.1 CMV Infection
          • 1.1.1.1.4.1.1 Incidence
          • 1.1.1.1.4.1.2 Diagnosis rate
          • 1.1.1.1.4.1.3 Target Patient Pool
          • 1.1.1.1.4.2 Sepsis
          • 1.1.1.1.4.2.1 Incidence
          • 1.1.1.1.4.2.2 Diagnosis rate
          • 1.1.1.1.4.2.3 Target Patient Pool
          • 1.1.1.1.4.3 Antimicrobial Resistance
          • 1.1.1.1.4.3.1 Microbe Resistance
          • 1.1.1.1.4.3.2 Key Causative Agent
          • 1.1.1.1.4.3.3 Preventive Measures to Limit AMR
          • 1.1.1.1.4.3.4 Challenges
    • 1.1.2 Most Preferred Platform for Infectious Disease Diagnosis
      • 1.1.2.1 Rapid Antigen Test (RAT)
      • 1.1.2.2 Polymerase Chain Reaction (PCR)
      • 1.1.2.3 Next Generation Sequencing (NGS)
    • 1.1.3 Timeline of Emerging Technologies for Infectious Disease Diagnostics
    • 1.1.4 Advantages and Limitations of Emerging Infectious Disease Diagnostic Technologies
    • 1.1.5 Advantages and Limitations of Point-of-Care Emerging Infectious Disease Diagnostics
  • 1.2 Market Dynamics
    • 1.2.1 Market Opportunities and Trends
    • 1.2.2 Market Drivers
      • 1.2.2.1 Impact Analysis
    • 1.2.3 Market Restraints
      • 1.2.3.1 Impact Analysis

2. India Emerging Infectious Disease Diagnostics Market Analysis (by Application), $Million, 2023-2035

  • 2.1 Overview
  • 2.2 Laboratory Testing
  • 2.3 Point-of-Care Testing

3. India Emerging Infectious Disease Diagnostics Market Analysis (by Technology), $Million, 2023-2035

  • 3.1 Overview
  • 3.2 PCR
    • 3.2.1 Real Time PCR
    • 3.2.2 Digital PCR
  • 3.3 Immunodiagnostics
  • 3.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 3.5 Next Generation Sequencing (NGS)
  • 3.6 Other Technologies

4. India Emerging Infectious Disease Diagnostics Market Analysis (by Type of Infection), $Million, 2023-2035

  • 4.1 Overview
  • 4.2 Bacterial
  • 4.3 Viral
  • 4.4 Fungal
  • 4.5 Other Infections (Parasite)

5. India Emerging Infectious Disease Diagnostics Market Analysis (By Disease Type), $Million, 2023-2035

  • 5.1 Overview
  • 5.2 Respiratory Infection
  • 5.3 Gastrointestinal Infection
  • 5.4 Sexually Transmitted Infections (STIs)
  • 5.5 Neurological Infection
  • 5.6 Post-Transplant Infection
  • 5.7 Other Infection

6. India Emerging Infectious Disease Diagnostics Market Analysis (By End User), $Million, 2023-2035

  • 6.1 Overview
  • 6.2 Hospitals and Clinics
  • 6.3 Diagnostic Laboratories
  • 6.4 Other End User

7. India Emerging Infectious Disease Diagnostics Market - Competitive Benchmarking and Company Profiles

  • 7.1 Competitive Benchmarking
  • 7.2 Competitive Landscape
    • 7.2.1 Key Strategies and Developments by Company
      • 7.2.1.1 Funding Activities
      • 7.2.1.2 Mergers and Acquisitions
      • 7.2.1.3 Regulatory Approvals
      • 7.2.1.4 Partnerships, Collaborations and Business Expansions
    • 7.2.2 Key Developments Analysis
    • 7.2.3 Company Share Analysis
  • 7.3 Company Profiles
    • 7.3.1 Abbott Laboratories
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Product Portfolio
      • 7.3.1.3 Target Customers/End Users
      • 7.3.1.4 Analyst View
    • 7.3.2 Becton, Dickson and Company
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Product Portfolio
      • 7.3.2.3 Target Customers/End Users
      • 7.3.2.4 Analyst View
    • 7.3.3 bioMerieux S.A.
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Product Portfolio
      • 7.3.3.3 Target Customers/End Users
      • 7.3.3.4 Analyst View
    • 7.3.4 Bio-Rad Laboratories, Inc
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Product Portfolio
      • 7.3.4.3 Target Customers/End Users
      • 7.3.4.4 Analyst View
    • 7.3.5 Co-Diagnostics, Inc.
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Product Portfolio
      • 7.3.5.3 Target Customers/End Users
      • 7.3.5.4 Analyst View
    • 7.3.6 Danaher Corporation
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Product Portfolio
      • 7.3.6.3 Target Customers/End Users
      • 7.3.6.4 Analyst View
    • 7.3.7 DiaSorin S.p.A
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Product Portfolio
      • 7.3.7.3 Target Customers/End Users
      • 7.3.7.4 Analyst View
    • 7.3.8 F. Hoffmann-La Roche Ltd
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Product Portfolio
      • 7.3.8.3 Target Customers/End Users
      • 7.3.8.4 Analyst View
    • 7.3.9 Hologic, Inc
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Product Portfolio
      • 7.3.9.3 Target Customers/End Users
      • 7.3.9.4 Analyst View
    • 7.3.10 QIAGEN N.V.
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Product Portfolio
      • 7.3.10.3 Target Customers/End Users
      • 7.3.10.4 Analyst View
    • 7.3.11 Thermo Fisher Scientific, Inc.
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Product Portfolio
      • 7.3.11.3 Target Customers/End Users
      • 7.3.11.4 Analyst View
    • 7.3.12 Siemens Healthineers AG
      • 7.3.12.1 Company Overview
      • 7.3.12.2 Product Portfolio
      • 7.3.12.3 Target Customers/End Users
      • 7.3.12.4 Analyst View
  • 7.4 Emerging Companies Snapshot
    • 7.4.1 Trivitron Healthcare
    • 7.4.2 Genes2Me
    • 7.4.3 CrisprBits
    • 7.4.4 D-NOME Pvt Ltd.

8. Research Methodology

List of Figures

  • Figure: India Emerging Infectious Disease Diagnostics Market, Market Dynamics Impact Analysis
  • Figure: India Emerging Infectious Disease Diagnostics Market Coverage
  • Figure: India Emerging Infectious Disease Diagnostics Market Key Trends, Impact Analysis, 2022-2025
  • Figure: India Emerging Infectious Disease Diagnostics Market, Patent Analysis, January 2022-March 2025
  • Figure: India Emerging Infectious Disease Diagnostics Market, Competitive Landscape, January 2022-March 2025

List of Tables

  • Table: India Emerging Infectious Disease Diagnostics Market, Comparative Analysis
  • Table: India Emerging Infectious Disease Diagnostics Market, Regulatory Scenario
  • Table: India Emerging Infectious Disease Diagnostics Market, Impact Analysis
  • Table: India Emerging Infectious Disease Diagnostics Market (by Application), $Million, 2023-2035
  • Table: India Emerging Infectious Disease Diagnostics Market (by Technology), $Million, 2023-2035
  • Table: India Emerging Infectious Disease Diagnostics Market (by Type of Infection), $Million, 2023-2035
  • Table: India Emerging Infectious Disease Diagnostics Market (by Disease Type), $Million, 2023-2035
  • Table: India Emerging Infectious Disease Diagnostics Market (by End User), $Million, 2023-2035